
|Articles|February 1, 2004
Acne treatment comes of age
Waikoloa, Hawaii - The large, multicenter B.E.S.T. (Balancing Efficacy, Speed and Tolerability) clinical trial provides real-world data, reinforcing the conclusion that tazarotene 0.1 percent cream (Tazorac for acne) applied once daily in the evening is a highly and rapidly effective, well-tolerated treatment for acne vulgaris, said Dina N. Anderson, M.D., at the annual Hawaii Dermatology Seminar in January.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
JAK Inhibitors Show Comparable Safety to TNF Antagonists
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















